Home > Insider Trading > Filing (0001567619-18-007048)

Filing Details

Accession Number:: 0001567619-18-007048
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-11-28 17:09:50
Reporting Period:: 2018-11-26

Accepted Time:: 2018-11-28 17:09:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1581720	Loxo Oncology Inc.	LOXO	Pharmaceutical Preparations (2834)	462996673

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1640069	Jennifer Burstein	C/O Loxo Oncology, Inc. One Landmark Square, Suite 1122 Stamford CT 06901	Senior Vp Of Finance	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-11-26	1,250	$11.35	1,250	No	4	M	Direct
Common Stock	Disposition	2018-11-26	500	$151.57	750	No	4	S	Direct
Common Stock	Disposition	2018-11-26	250	$152.39	500	No	4	S	Direct
Common Stock	Disposition	2018-11-26	100	$153.30	400	No	4	S	Direct
Common Stock	Disposition	2018-11-26	300	$155.13	100	No	4	S	Direct
Common Stock	Disposition	2018-11-26	100	$156.04	0	No	4	S	Direct
Common Stock	Acquisiton	2018-11-27	1,250	$11.35	1,250	No	4	M	Direct
Common Stock	Disposition	2018-11-27	200	$137.89	1,050	No	4	S	Direct
Common Stock	Disposition	2018-11-27	350	$138.95	700	No	4	S	Direct
Common Stock	Disposition	2018-11-27	200	$140.94	500	No	4	S	Direct
Common Stock	Disposition	2018-11-27	200	$143.84	300	No	4	S	Direct
Common Stock	Disposition	2018-11-27	100	$147.09	200	No	4	S	Direct
Common Stock	Disposition	2018-11-27	100	$148.20	100	No	4	S	Direct
Common Stock	Disposition	2018-11-27	100	$151.55	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-11-26	1,250	$0.00	1,250	$11.35
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2018-11-27	1,250	$0.00	1,250	$11.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
21,250		2025-04-30	No	4	M	Direct
20,000		2025-04-30	No	4	M	Direct

Footnotes

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
Represents the aggregate of sales effected on the same day at different prices.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.09 to $152.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.21 to $152.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.69 to $155.37. per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.63 to $138.15 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.68 to $139.10 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.64 to $141.24 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.54 to $144.14 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.13 to $148.24 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments.